TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Conavi Medical ( (TSE:CNVI) ).
Conavi Medical has announced strategic leadership changes to support its upcoming U.S. commercialization phase. Mark Quick has been appointed as the new Chief Financial Officer, bringing extensive capital markets expertise to guide the company’s financial strategy and investor engagement. Meanwhile, the current CFO, Stefano Picone, will transition to a strategic role to ensure leadership continuity. These changes coincide with Conavi’s submission of its next-generation Novasight Hybrid IVUS/OCT system for FDA clearance, as the company builds infrastructure for its U.S. market launch, aiming to expand its presence in the largest market for intravascular imaging.
The most recent analyst rating on (TSE:CNVI) stock is a Buy with a C$1.00 price target. To see the full list of analyst forecasts on Conavi Medical stock, see the TSE:CNVI Stock Forecast page.
More about Conavi Medical
Conavi Medical is a commercial-stage medical device company that focuses on designing, manufacturing, and marketing imaging technologies to guide minimally invasive cardiovascular procedures. Their patented Novasight Hybrid System uniquely combines intravascular ultrasound (IVUS) and optical coherence tomography (OCT) into a single device, allowing simultaneous and co-registered imaging of coronary arteries. The first-generation Novasight Hybrid System is already cleared in the U.S., Canada, China, and Japan.
YTD Price Performance: -15.71%
Average Trading Volume: 25,715
Technical Sentiment Signal: Sell
Current Market Cap: C$31.53M
For a thorough assessment of CNVI stock, go to TipRanks’ Stock Analysis page.